Key signaling pathways and emerging mechanisms in HCC and their roles in disease development and treatment are reviewed to lead to novel therapeutic targets and the development of more effective, personalized treatment strategies.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related mortality worldwide. Despite advances in diagnosis and therapy, the prognosis for advanced HCC remains poor due to late-stage diagnosis, high recurrence rates, therapeutic resistance, and pronounced molecular heterogeneity. HCC development is driven by complex somatic gene alterations, epigenetic reprogramming, dysregulated signaling pathways, metabolic changes, and an immunosuppressive tumor microenvironment. Molecular profiling studies have identified key oncogenic pathways involved in HCC progression, including MAPK/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase), Wnt/β-catenin, PI3K/AKT/mTOR (Phosphoinositide 3-kinase/Protein Kinase B/mechanistic Target of Rapamycin), Hippo-YAP/TAZ, (Yes-associated protein/transcriptional co-activator with PDZ-binding motif) cell cycle regulators, and p53-mediated tumor suppression. These pathways coordinate critical cellular processes such as proliferation, survival, metabolism, invasion, and genomic stability. Emerging mechanisms, including cancer stem cell plasticity, immune evasion, epigenetic dysregulation, and steroid receptor coactivator (SRC)-dependent transcriptional regulation, further contribute to tumor progression and therapeutic resistance. Additionally, recent bioinformatic analyses suggest a potential role for progesterone-mediated oocyte maturation pathways in HCC, although their functional relevance remains unclear. A thorough understanding of these interconnected mechanisms could lead to novel therapeutic targets and the development of more effective, personalized treatment strategies for HCC. This review discusses key signaling pathways and emerging mechanisms in HCC and their roles in disease development and treatment.
MiR-770 has been introduced as a potential marker in the prognosis of various cancers as well as in the early identification of tumor formation, progression, and metastasis.
Therapeutic modulation of the SET-PP2A axis may provide a novel strategy for suppressing tumor progression and improving treatment outcomes, and further mechanistic studies and welldesigned clinical investigations are required to establish the therapeutic relevance of SET targeting and facilitate its integration into p...
Rohit Das, Shikha Yadav, Sudeshna Das et al.· Current Signal Transduction...· 0 citations
Experimental results from breast, lung, gastric, liver, hematological, and melanoma models suggest that dysregulated PDK1 signaling can increase the output of the PI3K-AKT-mTOR pathway, invasion, metabolic adaptation, and resistance to specific hormonal, chemotherapeutic, and targeted therapies.
Darshana Ballagere Honnasiddappa, M. Ramar, Tincy Biju et al.· International Journal of Bio...· 0 citations
Simple Summary Hepatocellular carcinoma (HCC), the predominant type of liver cancer, is one of the leading causes of cancer-related deaths worldwide, and many patients are diagnosed only after the disease has reached an advanced stage. Although new treatments, including targeted therapies and immunotherapy, have improv...
A. Chambers, Morgan Reeves, Abhishek P. Shrestha et al.· Current Oncology· 0 citations
As a biomarker, phosphorylated EIF4EBP1 levels predict tumor aggressiveness and treatment failure, positioning it as a critical node for precision oncology.
Wei-Jia Liu, Li-Li Hou, Dan-Dan Tang et al.· Frontiers in Bioscience· 0 citations
: Oral squamous cell carcinoma (OSCC) is an aggressive malignancy often diagnosed at advanced stages and associated with poor prognosis. This review aims to summarize the role of Kirsten rat sarcoma viral oncogene homolog (KRAS) signaling in OSCC progression, with particular emphasis on its involvement in the regulatio...
Bianca Voicu-Bălășea, Alexandra Popa, Florentina Rus et al.· Biocell (Mendoza)· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.